[1]
|
Burki, T.K. (2020) Coronavirus in China. Lancet Respiratory Medicine, 8, 238. https://doi.org/10.1016/S2213-2600(20)30056-4
|
[2]
|
Huang, C., Wang, Y., Li, X., Ren, I., Zhao, J., Hu, Y., et al. (2020) Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China. The Lancet, 395, 497-506. https://doi.org/10.1016/S0140-6736(20)30183-5 https://www.thelancet.com/journals/thelancet/article/PIIS0140-6736(20)30183-5/fulltext
|
[3]
|
Li, J.-Y., You, Z., Wang, Q., Zhou, Z.-J., Qiu, Y., Luo, R. and Ge, X.-Y. (2020) The Epidemic of 2019-Novel-Coronavirus (2019-nCov) Pneumonia and Insights for Emerging Infectious Diseases in the Future. Microbes and Infections, 22, 80-85. https://www.sciencedirect.com/science/article/pii/S1286457920300307 https://doi.org/10.1016/j.micinf.2020.02.002
|
[4]
|
Chen, J. (2020) Pathogenicity and Transmissibility of 2019-nCov—A Quick Overview and Comparison with Other Re-Emerging Viruses. Microbes and Infections, 22, 69-71. https://www.sciencedirect.com/science/article/pii/S1286457920300265 https://doi.org/10.1016/j.micinf.2020.01.004
|
[5]
|
Emami, A., Javanmardi, F., Pirbonyeh, N. and Akbari, A. (2020) Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis. Archives of Academic Emergency Medicine, 8, e35. http://journals.sbmu.ac.ir/aaem/index.php/AAEM/article/view/600/754
|
[6]
|
Guo, Y.-R., Cao, Q.-D., Hong, Z.-S., Tan, Y.-Y., Chen, S.-D., Jin, H.-J., Tan, K.-S., Wang, D.-Y. and Yan, Y. (2020) The Origin, Transmission and Clinical Therapies on Coronavirus Disease 2019 (COVID-19) Outbreak—An Update on the Status. Military Medical Research, 7, Article No. 11. https://doi.org/10.1186/s40779-020-00240-0
|
[7]
|
Yang, X., Yu, Y., Xu, J., Shu, H., Xia, J., et al. (2020) Clinical Course and Outcomes of Critically Ill Patients with SARS-CoV-2 Pneumonia in Wuhan, China: A Single-Centered, Retrospective, Observational Study. The Lancet Respiratory Medicine, 8, e26. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102538 https://doi.org/10.1016/S2213-2600(20)30079-5
|
[8]
|
Nicolson, G.L. (2008) Chronic Infections in Neurodegenerative and Neurobehavioral Diseases. Lab Medicine, 39, 291-299. https://academic.oup.com/labmed/article/39/5/291/2504709 https://doi.org/10.1309/96M3BWYP42L11BFU
|
[9]
|
Nicolson, G.L. and Haier, J. (2009) Role of Chronic Bacterial and Viral Infections in Neurodegenerative, Neurobehavioral, Psychiatric, Autoimmune and Fatiguing Illnesses: Part 1. British Journal of Medical Practitioners, 2, 20-28. https://www.bjmp.org/content/role-chronic-bacterial-and-viral-infections-neurodegenerative- neurobehavioral-psychiatric-au
|
[10]
|
Nicolson, G.L. and Haier, J. (2010) Role of Chronic Bacterial and Viral Infections in Neurodegenerative, Neurobehavioral, Psychiatric, Autoimmune and Fatiguing Illnesses: Part 2. British Journal of Medical Practitioners, 3, e301. https://www.bjmp.org/content/role-chronic-bacterial-and-viral-infections-neurodegenerative -neurobehavioural-psychiatric-a
|
[11]
|
Lo, S.-C., Dawson, M.S., Newton, P.B., et al. (1989) Association of the Virus-Like Infectious Agent Originally Reported in Patients with AIDS with Acute Fatal Disease in Previously Healthy Non-AIDS Patients. American Journal of Tropical Medicine and Hygiene, 41, 364-376. https://doi.org/10.4269/ajtmh.1989.41.364 https://www.ajtmh.org/content/journals/10.4269/ajtmh.1989.41.364
|
[12]
|
Izumikawa, K. (2016) Clinical Features of Severe or Fatal Mycoplasma pneumoniae Pneumonia. Frontiers in Microbiology, 7, Article No. 800. https://www.frontiersin.org/articles/10.3389/fmicb.2016.00800/full https://doi.org/10.3389/fmicb.2016.00800
|
[13]
|
Nicolson, G.L., Gan, R., Nicolson, N.L. and Haier, J. (2007) Evidence for Mycoplasma, Chlamydia pneunomiae and HHV-6 Co-Infections in the Blood of Patients with Autistic Spectrum Disorders. Journal of Neuroscience Research, 85, 1143-1148. https://doi.org/10.1002/jnr.21203
|
[14]
|
Nicolson, G.L., Gan, R. and Haier, J. (2003) Multiple Co-Infections (Mycoplasma, Chlamydia, Human Herpes Virus-6) in Blood of Chronic Fatigue Syndrome Patients: Association with Signs and Symptoms. Acta Pathologica Microbiologica Immunologica Scandanavia (APMIS), 111, 557-566. https://doi.org/10.1034/j.1600-0463.2003.1110504.x
|
[15]
|
Nicolson, G.L., Nicolson, N.L. and Haier, J. (2008) Chronic Fatigue Syndrome Patients Subsequently Diagnosed with Lyme Disease Borrelia burgdorferi: Evidence for Mycoplasma Species Co-Infections. Journal of Chronic Fatigue Syndrome, 14, 5-17. https://doi.org/10.1080/10573320802091809
|
[16]
|
Berghoff, W. (2012) Chronic Lyme Disease and Co-Infections: Differential Diagnosis. Open Neurology Journal, 6, 158-178. https://openneurologyjournal.com/VOLUME/6/PAGE/158/FULLTEXT https://doi.org/10.2174/1874205X01206010158
|
[17]
|
Chiu, C.-Y., Chen, C.-J., Wong, K.-S., Tsai, M.-H., Chiu, C.-H. and Huang, Y.-C. (2015) Impact of Bacterial and Viral Coinfection on Mycoplasmal Pneumonia in Childhood Community-Acquired Pneumonia. Journal of Microbiology, Immunology and Infection, 48, 51-56. https://doi.org/10.1016/j.jmii.2013.06.006 https://www.sciencedirect.com/science/article/pii/S1684118213001102
|
[18]
|
Hon, E.K.L., Ip, M., Chu, W.C.W. and Wong, W. (2012) Megapneumonia Coinfection: Pneumococcus, Mycoplasma pneumoniae, and Metaneumovirus. Case Reports in Medicine, 2012, Article ID: 310104. https://doi.org/10.1155/2012/310104 https://www.hindawi.com/journals/crim/2012/310104
|
[19]
|
Kim, J.H., Kwon, J.H., Lee, J.-Y., Lee, J.S., Ryu, J.-M., Kim, S.-H., Lim, K.S. and Kim, W.Y. (2018) Clinical Features of Mycoplasma pneumoniae Coinfection and Need for Its Testing in Influenza Pneumonia Patients. Journal of Thoracic Disease, 10, 6118-6127. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6297417 https://doi.org/10.21037/jtd.2018.10.33
|
[20]
|
Toikka, P., Juvén, T., Virkki, R., Leinonen, M., Mertsola, J. and Ruuskanen, O. (2000) Streptococcus pneumoniae and Mycoplasma pneumonia in Community-Acquired Pneumonia. Archives of Disease in Childhood, 83, 413-414. https://adc.bmj.com/content/archdischild/83/5/413.full.pdf https://doi.org/10.1136/adc.83.5.413
|
[21]
|
Berrajah, L.F., Ben Slama, K.A., Khbou, I., Gargouri, S., Chtourou, A., Znazen, A., et al. (2018) Virus et Bactéries Atypiques Détectés dan les Infections Respiratoires Basses Communautaires de L’enfant Dans le Region de Sfax en Tunisie. Bulletin de la Société de Pathologie Exotique, 111, 90-98. https://bspe.revuesonline.com/article.jsp?langue=en&articleId=39461 https://doi.org/10.3166/bspe-2018-0024
|
[22]
|
Zahariadis, G., Gooley, T.A., Ryall, P., Hutchinson, C., Latchford, M.I., Fearon, M.A. and Jamieson, F.B. (2006) Risk of Ruling out Severe Acute Respiratory Syndrome by Ruling in Another Diagnosis: Variable Incidence of Atypical Bacteria Coinfection Based on Diagnostic Assays. Canadian Respiratory Journal, 13, 17-22. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2539008 https://doi.org/10.1155/2006/862797
|
[23]
|
Borak, J. and Lefkowitz, R.Y. (2016) Bronchial Hyperresponsiveness. Occupational Medicine, 66, 95-105. https://academic.oup.com/occmed/article/66/2/95/2750597 https://doi.org/10.1093/occmed/kqv158
|
[24]
|
Parrott, G.L., Kinjo, T. and Fujita, J. (2016) A Compendium for Mycoplasma pneumoniae. Frontiers in Microbiology, 7, Article No. 513. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4828434/pdf/fmicb-07-00513.pdf https://doi.org/10.3389/fmicb.2016.00513
|
[25]
|
Seggev, J.S., Sedmak, G.V. and Kurup, V. (1996) Isotype-Specific Antibody Responses to Acute Mycoplasma pneumoniae Infection. Annals of Allergy, Asthma and Immunology, 77, 67-73. https://doi.org/10.1016/S1081-1206(10)63482-5 https://www.annallergy.org/article/S1081-1206(10)63482-5/pdf
|
[26]
|
Lim, K.G.E., Chong, V.C.L., Chan, S.S.W., Ong, K.H. and Kuperan, P. (2020) COVID-19 and Mycoplasma pneumoniae Coinfection. American Journal of Hematology, 95, 1. https://doi.org/10.1002/ajh.25785
|
[27]
|
Gao, Z., Gao, L., Chen, X. and Xu, Y. (2020) A 49-Year-Old Women Co-Infected with SARS-CoV-2 and Mycoplasma—A Case Report. Infectious Diseases. https://www.researchsquare.com/article/rs-16376/v1 https://doi.org/10.21203/rs.3.rs-16376/v1
|
[28]
|
Geng, Y.-J., Wei, Z.-Y., Qian, H.-Y., Huang, J., Lodato, R. and Castriotta, R.J. (2020) Pathophysiological Characteristics and Therapeutic Approaches for Pulmonary Injury and Cardiovascular Complications of Coronavirus Disease 2019. Cardiovascular Pathology. (In Press) https://doi.org/10.1016/j.carpath.2020.107228
|
[29]
|
Bhatraju, P.K., Ghassemieh, B.J., Nichols, M., Kim, R., Jerome, K.R., Nalla, A.K., et al. (2020) Covid-19 in Critically Ill Patients in the Seattle Region—Case Series. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2004500 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7143164
|
[30]
|
Papa, S. (1996) Mitochondrial Oxidative Phosphorylation Changes in the Life Span. Molecular Aspects and Physiopathological Implications. Biochimica et Biophysica Acta, 1276, 87-105. https://doi.org/10.1016/0005-2728(96)00077-1 https://www.sciencedirect.com/science/article/pii/0005272896000771
|
[31]
|
Bohovych, I. and Khalimonchuk, O. (2016) Sending Out an SOS: Mitochondria as a Signaling Hub. Frontiers in Cell and Developmental Biology, 4, a109. https://www.frontiersin.org/articles/10.3389/fcell.2016.00109/full https://doi.org/10.3389/fcell.2016.00109
|
[32]
|
Murphy, M.P. and Hartley, R.C. (2018) Mitochondria as a Therapeutic Target for Common Pathologies. Nature Reviews in Drug Discovery, 17, 865-886. https://www.nature.com/articles/nrd.2018.174 https://doi.org/10.1038/nrd.2018.174
|
[33]
|
Khan, M., Syed, G.H., Kim, S.-J. and Siddiqui, K. (2015) Mitochondrial Dynamics and Viral Infections: a Close Nexus. Biochimica et Biophysica Acta, 1853, 2822- 2833. https://www.sciencedirect.com/science/article/pii/S0167488915000099 https://doi.org/10.1016/j.bbamcr.2014.12.040
|
[34]
|
Shi, C.S., Qi, H.Y., Boularan, C., Huang, N.N., Abu-Asab, M., Shelhamer, J.H. and Kehrl, J.H. (2014) SARS-Coronaviruses Open Reading Frame-9b Suppresses Innate Immunity by Targeting Mitochondria and the MAVS/TRAF3/TRAF6 Signalosome. Journal of Immunology, 193, 3080-3089. https://doi.org/10.4049/jimmunol.1303196 https://www.jimmunol.org/content/jimmunol/193/6/3080.full.pdf
|
[35]
|
Sun, G., Xu, X., Wang, Y., Shen, X., Chen, Z. and Yang, J. (2008) Mycoplasma pneumoniae Infection Induces Reactive Oxygen Species and DNA Damage in A549 Human Lung Carcinoma Cells. Infection and Immunity, 76, 4405-4413. https://iai.asm.org/content/iai/76/10/4405.full.pdf https://doi.org/10.1128/IAI.00575-08
|
[36]
|
Xu, Z., Wang, Y., Zhang, J., Huang, L., Zhang, C., Liu, S., Zhao, P., et al. (2020) Pathological Findings of COVID-19 Associated with Acute Respiratory Distress Syndrome. The Lancet Respiratory Medicine, 8, 420-422. https://www.thelancet.com/pdfs/journals/lanres/PIIS2213-2600(20)30076-X.pdf https://doi.org/10.1016/S2213-2600(20)30076-X
|
[37]
|
Nicolson, G.L. and Ash, M.E. (2017) Membrane Lipid Replacement for Chronic Illnesses, Aging and Cancer Using Oral Glycerolphospholipid Formulations with Fructooligosaccharides to Restore Phospholipid Function in Cellular Membranes, Organelles, Cells and Tissues. Biochimica et Biophysica Acta Biomembranes, 1859, 1704-1724. https://doi.org/10.1016/j.bbamem.2017.04.013
|
[38]
|
Nicolson, G.L., Settineri, R. and Ellithorpe, E. (2012) Glycophospholipid Formulation with NADH and CoQ10 Significantly Reduces Intractable Fatigue in Chronic Lyme Disease Patients: Preliminary Report. Functional Foods in Health and Disease, 2, 35-47. http://www.functionalfoodscenter.net/files/50313126.pdf https://doi.org/10.31989/ffhd.v2i3.100
|
[39]
|
Marchello, C., Dale, A.P., Thai, T.N., Han, D.S. and Ebell, M.H. (2016) Prevalence of Atypical Pathogens in Patients with Cough and Community-Acquired Pneumonia: A Meta Analysis. Annals of Family Medicine, 14, 552-566. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5389400 https://doi.org/10.1370/afm.1993
|
[40]
|
Fernald, G.W. (1983) Immunologic Mechanisms Suggested in the Association of M. pneumoniae Infection and Extrapulmonary Disease: A Review. Yale Journal of Biology and Medicine, 56, 475-479.
|
[41]
|
Shimizu, T. (2016) Inflammation-Inducing Factors of Mycoplasma pneumoniae. Frontiers in Microbiology, 7, Article No. 414. https://www.frontiersin.org/articles/10.3389/fmicb.2016.00414/full https://doi.org/10.3389/fmicb.2016.00414
|
[42]
|
Simecka, J.W., Ross, S.E., Cassell, G.H. and Davis, J.K. (1993) Interactions of Mycoplasmas with B Cells: Antibody Production and Nonspecific Effects. Clinical Infectious Diseases, 17, S176-S182. https://academic.oup.com/cid/article-abstract/17/Supplement_1/S176/309747?redirectedFrom=fulltext https://doi.org/10.1093/clinids/17.Supplement_1.S176
|
[43]
|
Quentmeier, H., Schmitt, E., Kirchhoff, H., Grote, W. and Muhlradt, P.F. (1990) Mycoplasma fermentans-Derived High-Molecular-Weight Material Induces Interleukin-6 Release in Cultures of Murine Macrophages and Human Monocytes. Infection and Immunity, 58, 1273-1280. https://iai.asm.org/content/58/5/1273 https://doi.org/10.1128/IAI.58.5.1273-1280.1990
|
[44]
|
Yi, Y., Lagniton, P.N.P., Ye, S., Li, E. and Xu, R.-H. (2020) COVID-19: What Has Been Learned and to Be Learned about the Novel Coronavirus Disease. International Journal of Biological Sciences, 16, 1753-1766. https://www.ijbs.com/v16p1753.pdf https://doi.org/10.7150/ijbs.45134
|
[45]
|
Lu, X., Pan, J., Tao, J. and Guo, D. (2011) SARS-CoV Nucleocapsid Protein Antagonizes IFN-beta Response by Targeting Initial Step of IFN-beta Induction Pathway, and Its C-Terminal Region Is Critical for the Antagonism. Virus Genes, 42, 37-45. https://link.springer.com/article/10.1007/s11262-010-0544-x https://doi.org/10.1007/s11262-010-0544-x
|
[46]
|
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., et al. (2020) Clinical Characteristics of Coronavirus Disease 2019 in China. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2002032
|
[47]
|
Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qui, Y., et al. (2020) Epidemiological and Clinical Characteristics of 99 Cases of 2019 Novel Coronavirus Pneumonia in Wuhan, China: A Descriptive Study. The Lancet Respiratory Disease, 395, 507-513. https://doi.org/10.1016/S0140-6736(20)30211-7
|
[48]
|
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., et al. (2020) Clinical Course and Risk Factors for Mortality of Adult Inpatients with COVID-19 in Wuhan, China: A Retrospective Cohort Study. The Lancet, 395, 1054-1062. https://www.thelancet.com/pdfs/journals/thelancet/PIIS0140-6736(20)30566-3.pdf https://doi.org/10.1016/S0140-6736(20)30566-3
|
[49]
|
Klok, F.A., Kruip, M.J.H.A., van der Meer, N.J.M., Arbous, M.S., Gommers, D.A.M.P.J., Kant, K.M., et al. (2020) Incidence of Thrombotic Complications in Critically Ill ICU Patients with COVID-19. Thrombosis Research, 191. https://www.thrombosisresearch.com/article/S0049-3848(20)30120-1/pdf https://doi.org/10.1016/j.thromres.2020.04.013
|
[50]
|
Inamura, N., Miyashita, N., Hasegawa, S., Kato, A., Fukuda, Y., Saitoh, A., Kondo, E., et al. (2014) Management of Refractory Mycoplasma pneumoniae: Utility of Measuring Serum Lactate Dehydrogenase Level. Journal of Infection and Chemotherapy, 20, 270-273. https://doi.org/10.1016/j.jiac.2014.01.001 https://www.sciencedirect.com/science/article/abs/pii/S1341321X14000737
|
[51]
|
Nesser, O.L., Vukajlovic, T., Felder, L., Haubitz, S., Hammerer-Lercher, A., Ottiger, C., Mueller, B., Schuetz, P. and Fux, C.A. (2019) A High C-Reactive Protein/Procalcitonin Ratio Predicts Mycoplasma pneumoniae Infection. Clinical Chemistry and Laboratory Medicine, 57, 1638-1646. https://www.degruyter.com/view/journals/cclm/57/10/article-p1638.xml https://www.ncbi.nlm.nih.gov/pubmed/31128571 https://doi.org/10.1515/cclm-2019-0194
|
[52]
|
Bar Meir, E., Amital, H., Levy, Y., Kneller, A., Bar-Dayan, Y. and Shoenfeld, Y. (2000) Mycoplasma-pneumoniae-Induced Thrombotic Thrombocytopenic Purpura. Acta Haematologica, 103, 112-115. https://doi.org/10.1159/000041030 https://www.karger.com/Article/Abstract/41030
|
[53]
|
Rathinam, V.A.K. and Fitzgerald, K.A. (2011) Cytosolic Surveillance and Antiviral Immunity. Current Opinion in Virology, 1, 455-462. https://www.sciencedirect.com/science/article/abs/pii/S1879625711001696 https://doi.org/10.1016/j.coviro.2011.11.004
|
[54]
|
Totura, A.L. and Baric, R.S. (2012) SARS Coronavirus Pathogenesis: Host Innate Immune Responses and Viral Antagonism of Interferon. Current Opinion in Virology, 2, 264-275. https://doi.org/10.1016/j.coviro.2012.04.004 https://www.sciencedirect.com/science/article/pii/S1879625712000715-bib021054
|
[55]
|
Cameron, M.J., Ran, L., Xu, L., Danesh, A., Bermejo-Martin, J.F., Cameron, C.M., Nuller, M.P., et al. (2007) Interferon-Mediated Immunopathological Events Are Associated with Atypical Innate and Adaptive Immune Responses in Patients with Severe Acute Respiratory Syndrome. Journal of Virology, 81, 8692-8706. https://jvi.asm.org/content/81/16/8692 https://doi.org/10.1128/JVI.00527-07
|
[56]
|
Rottem, S. (2003) Interaction of Mycoplasmas with Host Cells. Physiological Reviews, 83, 417-432. https://doi.org/10.1152/physrev.00030.2002
|
[57]
|
He, J., Liu, M., Ye, Z., Tan, T., Liu, X., You, X., Zeng, Y. and Wu, Y. (2016) Insights into the Pathogenesis of Mycoplasma penumoniae. Molecular Medicine Reports, 14, 4030-4036. https://www.spandidos-publications.com/mmr/14/5/4030 https://doi.org/10.3892/mmr.2016.5765
|
[58]
|
Baseman, J.B. and Tully, J.G. (1997) Mycoplasmas: Sophisticated, Reemerging, and Burdened by Their Notoriety. Emerging Infectious Diseases, 3, 21-32. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2627593/pdf/9126441.pdf https://doi.org/10.3201/eid0301.970103
|
[59]
|
Minion, F.C., Jarvill-Taylor, K.J., Billings, D.E. and Tigges, E. (1993) Membrane-Associated Nuclease Activities in Mycoplasmas. Journal of Bacteriology, 175, 7842-7847. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC206960 https://doi.org/10.1128/JB.175.24.7842-7847.1993
|
[60]
|
Saitoh, S., Wada, T., Narita, M., Kohsaka, S., Mizukami, S., Togashi, T. and Kajii, N. (1993) Mycoplasma pneumoniae Infection May Cause Striatal Lesions Leading to Acute Neurologic Dysfunction. Neurology, 43, 2150-2151. https://doi.org/10.1212/WNL.43.10.2150
|
[61]
|
Komada, Y., Zhang, X.L., Zhou, Y.W., Ido, M. and Azuma, E. (1997) Apoptotic Cell Death of Human Lymphoblastoid Cells Induced by Arginine Deaminase. International Journal of Hematology, 65, 129-141. https://doi.org/10.1016/S0925-5710(96)00538-5
|
[62]
|
Nicolson, G.L. (2019) Pathogenic Mycoplasma Infections in Chronic Illnesses: General Considerations in Selecting Conventional and Integrative Treatments. International Journal of Clinical Medicine, 10, 477-522. https://www.scirp.org/journal/paperinformation.aspx?paperid=95720 https://doi.org/10.4236/ijcm.2019.1010041
|
[63]
|
Rawadi, G., Roman-Roman, S., Castedo, M., Dutilleul, V., Susin, S., Marchetti, P., Geuskens, M. and Kroemer, G. (1996) Effects of Mycoplasma fermentans on the Myelomonocytic Linage. Different Molecular Endities with Cytokine-Inducing and Cytocidal Potential. Journal of Immunology, 156, 670-678. https://www.jimmunol.org/content/156/2/670
|
[64]
|
Waites, K.B., Xiao, L., Liu, Y., Balish, M.F. and Atkinson, T.P. (2017) Mycoplasma pneumonia from the Respiratory Tract and Beyond. Clinical Microbiology Reviews, 30, 747-809. https://doi.org/10.1128/CMR.00114-16
|
[65]
|
Becker, A., Kannan, T.R., Taylor, A.B., Pakhornova, O.N., Zhang, Y., Somarajan, S.R., Galaleldeen, A., Holloway, S.P., Baseman, J.B. and Hart, P.J. (2015) Structure of CARDS Toxin, a Unique ADP-Ribosylating and Vacuolating Cytotoxin from Mycoplasma pneumoniae. Proceedings of the National Academy of Sciences USA, 112, 5165-5170. https://doi.org/10.1073/pnas.1420308112
|
[66]
|
Muir, M.T., Cohn, S.M., Louden, C., Kannan, T.R. and Baseman, J.B. (2011) Novel Toxin Assays Implicate Mycoplasma pneumoniae in Prolonged Ventilator Course and Hypoxemia. Chest, 139, 305-310. https://doi.org/10.1378/chest.10-1222 https://journal.chestnet.org/article/S0012-3692(11)60069-X/pdf
|
[67]
|
Wang, Y., Lu, X., Chen, H., Chen, T., Su, N., Huang, F., Zhou, J., et al. (2020) Clinical Course and Outcomes of 344 Intensive Care Patients with COVID-19. American Journal of Respiratory and Critical Care Medicine. (In Press) https://doi.org/10.1164/rccm.202003-0736LE
|
[68]
|
Matute-Bello, G., Frevert, C.W. and Martin, T.R. (2008) Animal Models of Acute Lung Injury. American Journal of Physiology-Lung Cellular and Molecular Physiology, 295, L379-L399. https://doi.org/10.1152/ajplung.00010.2008
|
[69]
|
Teijaro, J.R. (2017) Cytokine Storms in Infectious Diseases. Seminars in Immunopathology, 39, 501-517. https://doi.org/10.1007/s00281-017-0640-2 https://link.springer.com/article/10.1007/s00281-017-0640-2
|
[70]
|
Tisoncik, J.R., Korth, M.J., Simmons, C.P., Farrar, J., Martin, T.R. and Katze, M.G. (2012) Into the Eye of the Cytokine Storm. Microbiology and Molecular Biology Reviews, 76, 16-32. https://mmbr.asm.org/content/76/1/16 https://doi.org/10.1128/MMBR.05015-11
|
[71]
|
Nicholls, J., Dong, X.-P., Jang, G. and Peiris, M. (2003) SARS: Clinical Virology and Pathogenesis. Respirology, 8, S6-S8. https://doi.org/10.1046/j.1440-1843.2003.00517.x
|
[72]
|
Yang, J., Hooper, W.C., Phillips, D.J. and Talkington, D.F. (2002) Regulation of Pro-Inflammatory Cytokines in Human Lung Epithelial Cells Infected with Mycoplasma pneumoniae. Infection and Immunity, 70, 3649-3655. https://iai.asm.org/content/70/7/3649 https://doi.org/10.1128/IAI.70.7.3649-3655.2002
|
[73]
|
Nicolson, G.L., Nasralla, M.Y. and Nicolson, N.L. (1998) The Pathogenesis and Treatment of Mycoplasmal Infections. Antimicrobics and Infectious Diseases Newsletter, 17, 81-87. https://doi.org/10.1016/S1069-417X(00)88885-8 https://www.sciencedirect.com/journal/antimicrobics-and-infectious-diseasesnewsletter/vol/17/issue/11
|
[74]
|
Sauter, P.M., van Rossum, A.M.C. and Vink, C. (2014) Mycoplasma pneumoniae in Children: Carriage, Pathogenesis and Antibiotic Resistance. Current Opinion in Infectious Diseases, 27, 220-227. https://doi.org/10.1097/QCO.0000000000000063 https://journals.lww.com/co-infectiousdiseases/Abstract/2014/06000/Mycoplasma_pneumonia e_in_children___carriage,.3.aspx
|
[75]
|
Kenny, G.E. and Cartwright, F.D. (2001) Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, Dalfopristin, Dirithromycin, Evernimicin, Gatifloxacin, Linezolid, Moxifloxacin, Quinupristin-Dalfopristin, and Telithromycin Compared to Their Susceptibilities to Reference Macrolides, Tetracyclines, and Quinolones. Antimicrobial Agents and Chemotherapy, 45, 2604-2608. https://aac.asm.org/content/45/9/2604 https://doi.org/10.1128/AAC.45.9.2604-2608.2001
|
[76]
|
Arai, S., Gohara, Y., Kuwano, K. and Kawashima, T. (1992) Antimycoplasmal Activities of New Quinolones, Tetracyclines and Macrolides against Mycoplasma pneumoniae. Antimicrobial Agents and Chemotherapy, 36, 1322-1324. https://aac.asm.org/content/36/6/1322 https://doi.org/10.1128/AAC.36.6.1322
|
[77]
|
Renaudin, H. and Bébéar, C. (1990) Comparative in Vitro Activity of Azithromycin, Clarithromycin, Erythromycin and Lomefloxacin against Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum. European Journal of Clinical Microbiology and Infectious Diseases, 9, 838-841. https://link.springer.com/article/10.1007/BF01967388 https://doi.org/10.1007/BF01967388
|
[78]
|
Cao, B., Ren, L.-L., Zhao, R., Gonzalez, R., Song, S.-F., Bai, L., Yin, Y.D., et al. (2010) Viral and Mycoplasma pneumoniae Community-Acquired Pneumonia and Novel Clinical Outcome Evaluation in Ambulatory Adult Patients in China. European Journal of Clinical Microbiology and Infectious Disease, 29, 1443-1448. https://link.springer.com/article/10.1007/s10096-010-1003-2 https://doi.org/10.1007/s10096-010-1003-2
|
[79]
|
Sch?gler, A., Kopf, B.S., Edwards, M.R., Johnston, S.L., Casaulta, C, Kleninger, E., Jung, A., Moeller, A., et al. (2015) Novel Antiviral Properties of Azithromycin in Cystic Fibrosis Airway Epithelial Cells. European Respiratory Journal, 45, 428-439. https://erj.ersjournals.com/content/45/2/428 https://doi.org/10.1183/09031936.00102014
|
[80]
|
Retallack, H., Di Lullo, E., Arias, C., Knopp, K.A., Laurie, M.T. and Sandoval-Espinosa, C. (2016) Zika Virus Cell Tropism in the Developing Human Brain and Inhibition by Azithromycin. Proceedings of the National Academy of Sciences USA, 113, 14408-14413. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102549 https://doi.org/10.1073/pnas.1618029113
|
[81]
|
Rubin, B.K. and Henke, M.O. (2004) Immunomodulatory Activity and Effectiveness of Macrolides in Chronic Airway Disease. Chest, 125, 70S-78S. https://www.ncbi.nlm.nih.gov/pubmed/14872003 https://doi.org/10.1378/chest.125.2_suppl.70S
|
[82]
|
Min, J.-Y. and Jang, Y.J. (2012) Macrolide Therapy in Respiratory Viral Infections. Mediators of Inflammation, 2012, Article ID: 649570. https://www.hindawi.com/journals/mi/2012/649570 https://doi.org/10.1155/2012/649570
|
[83]
|
Porter, J.D., Watson, J., Roberts, L.R., Gill, S.K., Groves, H., Dhariwal, J., Almond, M.H., et al. (2016) Indentification of Novel Macrolides with Antibacterial, Anti-Inflammatory and Type I and III INF-Augmenting Activity in Airway Epithelium. Journal of Antimicrobial Chemotherapy, 71, 2767-2781. https://academic.oup.com/jac/article/71/10/2767/2388101 https://doi.org/10.1093/jac/dkw222
|
[84]
|
Lu, Z.K., Yuan, J., Li, M., Sutton, S.S., Rao, G.A., Jacob, S. and Bennett, C.L. (2015) Cardiac Risks Associated with Antibiotics: Azithromycin and Levofloxacin. Expert Opinion on Drug Safety, 129, 715-724. https://www.tandfonline.com/doi/full/10.1517/14740338.2015.989210?scroll=top&needAccess=true https://doi.org/10.1517/14740338.2015.989210
|
[85]
|
Gautret, P., Lagier, J.-C., Parola, P., Hoang, V.T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., et al. (2020) Hydroxychloroquine and Azithromycin as a Treatment of COVID-19: Results of an Open Label Non-Randomized Clinical Trial. International Journal of Antimicrobial Agents, 2020, Article ID: 105949. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102549 https://doi.org/10.1016/j.ijantimicag.2020.105949
|
[86]
|
Chukwudi, C.U. (2016) rRNA Binding Sites and the Molecular Mechanism of Action of the Tetracyclines. Antimicrobial Agents and Chemotherapy, 60, 4433-4441. https://aac.asm.org/content/aac/60/8/4433.full.pdf https://doi.org/10.1128/AAC.00594-16
|
[87]
|
Vincent, M.J., Bergeron, E., Benjannet, S., Eirkson, B.R., Rollin, P.E., Ksiazek, T.G., Seidah, N.G. and Nichol, S.T. (2005) Chloroquine Is a Potent Inhibitor of SARS Coronavirus Infections and Spread. Virology Journal, 2, Article No. 69. https://virologyj.biomedcentral.com/articles/10.1186/1743-422X-2-69#citeas https://doi.org/10.1186/1743-422X-2-69
|
[88]
|
Lim, H.-S., Im, J.-S., Cho, J.-Y., Bae, K.-S., Klein, T.A., Yeom, J.-S., Kim, T.-S., Choi, J.-C., Jang, I.-J. and Park, J.-W. (2009) Pharmacokinetics of Hydroxychloroquine and Its Clinical Implications in Chemoprophylaxis against Malaria Caused by Plasmodium vivax. Antimicrobial Agents and Chemotherapy, 53, 1468-1475. https://aac.asm.org/content/aac/53/4/1468.full.pdf https://doi.org/10.1128/AAC.00339-08
|
[89]
|
Titus, E.O. (1989) Recent Developments in the Understanding of the Pharmacokinetics and Mechanism of Action of Chloroquine. Therapeutic Drug Monitoring, 11, 369-379. https://doi.org/10.1097/00007691-198907000-00001 https://journals.lww.com/drug-monitoring/Abstract/1989/07000/Recent_Developments_in_the_ Understanding_of_the.1.aspx
|
[90]
|
Schroeder, M.E., Russo, S, Costa C., Hori, J., Tiscornia, I., Bollati-Fogolin, M., Zamboni, D.S., Ferreira, G., Cairoli, E. and Hill, M. (2017) Pro-Inflammatory Ca++-Activated K+ Channels Are Inhibited by Hydroxychoroquine. Nature Scientific Reports, 7, Article No. 1892. https://doi.org/10.1038/s41598-017-01836-8 https://www.nature.com/articles/s41598-017-01836-8-citeas
|
[91]
|
Gao, J., Tian, Z. and Yang, X. (2020) Breakthrough: Chloroquine Phosphate Has Shown Apparent Efficacy in Treatment of COVID-19 Associated Pneumonia in Clinical Studies. Bioscience Trends, 14, 72-73. https://doi.org/10.5582/bst.2020.01047 https://www.biosciencetrends.com/article/1883
|
[92]
|
Borba, M.G.S., Val, F.F.A., Sampaio, V.S., Alexandre, M.A.A., Melo, G.C., Brito, M., Mour?no, M.P.G., Brito-Sousa, J.D., et al. (2020) Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunct Therapy for Patients Hospitalized with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS2CoV-2) Infection: A Randomized Clinical Trial. JAMA Network Open, 3, e208857. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2765499 https://doi.org/10.1001/jamanetworkopen.2020.8857
|
[93]
|
Singh, A.K., Singh, A., Shaikh, A., Singh, R. and Misra, A. (2020) Chloroquine and Hydroxychloroquine in the Treatment of COVID-19 with or without Diabetes: A Systemematic Search and a Narrative Review with a Special Reference to India and Other Developing Countries. Diabetes and Metabolic Syndrome: Clinical Research & Reviews, 14, 241-246. https://doi.org/10.1016/j.dsx.2020.03.011 https://www.sciencedirect.com/science/article/pii/S1871402120300515
|
[94]
|
Li, H., Zhou, Y., Zhang, M., Wang, H., Zhao, Q. and Liu, J. (2020) Updated Approaches against SARS-CoV-2. Antimicrobial Agents and Chemotherapy. (In Press) https://aac.asm.org/content/aac/early/2020/03/18/AAC.00483-20.full.pdf https://doi.org/10.1128/AAC.00483-20
|
[95]
|
Nicolson, G.L., Ferreira de Mattos, G., Settineri, R., Costa, C., Ellithorpe, R., Rosenblatt, S., La Valle, J., Jimmenez, A. and Ohta, S. (2016) Clinical Effects of Hydrogen Administration: From Animal and Human Diseases to Exercise Medicine. International Journal of Clinical Medicine, 7, 32-76. https://doi.org/10.4236/ijcm.2016.71005
|
[96]
|
Montagnier, L. and Blanchard, A. (1993) Mycoplasmas as Co-Factors in Infection Due to the Human Immunodeficiency Virus. Clinical Infectious Diseases, 17, S309- S315. https://www.jstor.org/stable/4457254?seq=1
|
[97]
|
Blanchard, A. and Montagnier, L. (1994) AIDS Associated Mycoplasmas. Annual Review of Microbiology, 48, 687-712. https://www.annualreviews.org/doi/pdf/10.1146/annurev.mi.48.100194.00335194 https://doi.org/10.1146/annurev.mi.48.100194.003351
|
[98]
|
Chakraborty, S. and Das, G. (2020) Secondary Infection by Anaerobic Bacteria Possibly Ensues a Battle for Oxygen in SARS-CoV-2 Infected Patients: Anaerobe-Targeting Antibiotics (Like Doxyclcine/Metronidazole) to Supplement Azithromycin in the Treatment of COVID19? OSF Preprints, April 10. (In Press) https://doi.org/10.31219/osf.io/s48fv
|
[99]
|
Stricker, R.B. and Fesler, M.C. (2020) A Novel Plan to Deal with SARS-CoV-2 and COVID-19 Disease. Journal of Medical Virology, April 28. (In Press) https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.25945 https://doi.org/10.31219/osf.io/urzkd
|